Lung Cancer Treatment Resistance Mechanism Identified
Researchers found a protein regulator that helps drug-tolerant lung cancer cells survive therapy.
Updated on Oct. 5, 2026 in Cancer
Scientists have identified the BMF protein as a critical regulator of drug-tolerant persister cells in ALK-positive lung cancer. This discovery sheds light on how these cancers develop resistance to standard ALK-targeted therapies.
Why it matters
Understanding how cancer cells evade treatment is vital for improving long-term survival in patients with ALK- or ROS1-positive lung cancer. This research highlights specific pathways that may eventually allow physicians to better manage therapeutic resistance.
In a genome-wide CRISPR-Cas9 screening of patient-derived ALK-positive lung cancer cells, researchers found that BMF loss impairs apoptosis and promotes the growth of drug-tolerant cells. These findings were further observed in ROS1-positive cell lines.
The players
ALK-positive lung cancer
A form of non-small cell lung cancer characterized by specific gene mutations that respond to targeted tyrosine kinase inhibitor therapies.
ROS1-positive lung cancer
A rare subtype of non-small cell lung cancer that shares similar oncogenic drivers and treatment resistance pathways with ALK-positive cancer.
The details
When patients receive ALK-targeted therapy, a subset of cancer cells known as drug-tolerant persister (DTP) cells can survive, leading to treatment resistance. Researchers found that the protein BMF acts as a brake on these cells; when BMF is lost, cells survive more easily. By inhibiting MCL-1 or FOXO1, the study demonstrated a way to bypass this resistance and successfully induce cell death in BMF-deficient cancer models.
Timeline
BMF expression levels were observed to increase within 24 hours of starting ALK-TKI treatment.
Health Landscape
This finding advances the ongoing effort to understand ALK-targeted therapy resistance by identifying a new regulatory protein involved in cancer cell survival. It builds upon established knowledge regarding oncogene-driven lung cancer treatment, offering potential new targets for combination therapies.
While this laboratory research provides a foundation for future treatment strategies, it does not currently change standard care protocols for lung cancer patients. If you are undergoing treatment for ALK-positive lung cancer, these mechanisms are worth discussing with your oncologist.
The takeaway
The study reveals that BMF protein loss is a key factor in how certain lung cancers evade targeted therapy. Patients should continue to follow their current treatment plans and discuss any concerns about drug resistance or new clinical options with their oncology care team.
Further reading
For more on the current understanding of oncogenic drivers, visit our Cancer section.
More information
Read the complete peer-reviewed research article to learn more about the study findings.
